Altimmune, Inc.

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-03-13 EDT			5-day change	1st Jan Change
3.500 ^USD	-2.78%		-1.13%	-3.05%

03-12	Altimmune, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-12-2026 10:30 AM
03-06	B. Riley Adjusts Price Target on Altimmune to $13 From $18, Maintains Buy Rating	MT

Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000 Value Index

Published on 06/30/2025 at 01:08 pm EDT

S&P Capital IQ

ALTIMMUNE, INC.

-2.78%

Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 3000 Value Index

Latest news about Altimmune, Inc.

03-12	Altimmune, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-12-2026 10:30 AM
03-06	B. Riley Adjusts Price Target on Altimmune to $13 From $18, Maintains Buy Rating	MT
03-05	Altimmune Shares Fall After Q4 Results	MT
03-05	Altimmune, Inc., Q4 2025 Earnings Call, Mar 05, 2026
03-05	Altimmune, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-03	Obesity stocks slump on Novo's underwhelming 2026 sales forecast	RE
01-28	Barclays Initiates Coverage on Altimmune With Overweight Rating, $20 Price Target	MT
01-28	Altimmune Prices $75 Million Registered Direct Offering	MT
01-05	Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH	CI
01-05	Altimmune Says US FDA Grants Breakthrough Therapy Designation for Pemvidutide in MASH	MT
01-05	Altimmune receives FDA breakthrough therapy designation for pemvidutide in mash	RE
12-23	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
12-19	Altimmune, Inc. - Special Call
12-19	Altimmune, Inc. Announces Positive Topline Results from the Impact Phase 2B Mash Trial	CI
12-19	Altimmune Says Pemvidutide Showed "Significant" Improvements in MASH Patients at 48 Weeks	MT

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâ€™s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Employees

Sector

Biotechnology & Medical Research

More about the company